Johnson & Johnson COVID-19 vaccine

From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Johnson & Johnson COVID-19 vaccine
A vial of Janssen COVID-19 Vaccine
Vaccine description
Target SARS-CoV-2
Vaccine type Viral vector
Clinical data
Trade names Janssen COVID-19 Vaccine,[1][2] COVID-19 Vaccine Janssen[3]
Other names
License data
Routes of
ATC code
  • None
Legal status
Legal status

The Johnson & Johnson COVID-19 vaccine is a COVID-19 vaccine[12] that was developed by Janssen Vaccines in Leiden, Netherlands,[13] and its Belgian parent company Janssen Pharmaceuticals,[14] subsidiary of American company Johnson & Johnson.[15][16]

It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID-19.[3] The body's immune system responds to this spike protein to produce antibodies.[17] The vaccine requires only one dose and does not need to be stored frozen.[18][19]

The vaccine started clinical trials in June 2020, with Phase III trials involving around 43,000 people.[9] On 29 January 2021, Janssen announced that 28 days after a completed vaccination, the vaccine was 66% effective in a one-dose regimen in preventing symptomatic COVID-19, with an 85% efficacy in preventing severe COVID-19,[20][21][22] and 100% efficacy in preventing hospitalization or death caused by COVID-19.[1]

The most common side effects were pain at the injection site, headache, fatigue, muscle aches and nausea.[9][23] Most of these side effects occurred within one to two days following vaccination and were mild to moderate in severity and lasted one to two days.[23][24]

The vaccine has been granted an Emergency Use Authorization by the US Food and Drug Administration[25] and a conditional marketing authorisation by the European Medicines Agency.[11][26][27]